Novo Nordisk says it will launch a semaglutide pill for diabetes under the brand name Ozempic later this year. The company says the U.S. Food and Drug Administration approved the medication in three different doses which will become available to the public during the second quarter of 2026. Katherine Ward has this story and more in Health Matters for Feb. 5 , 2026.